Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMSC01 in Acute Ischemic Stroke
NCT04434768Phase 1Completed
- Sponsor
- Ever Supreme Bio-Technology
- Start
- Dec 2020
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord derived mesenchymal stem cells in ischemic stroke, sponsored by Ever Supreme Bio-Technology. Primary endpoints: Serious Adverse Events at 24 weeks, Suspected Unexpected Serious Adverse Reactions at 24 weeks and 1 more. Started Dec 2020; status: completed.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04434768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04434768.